Acrivon Therapeutics, Inc.

Develops precision cancer therapies by matching patients to drugs using its proteomics platform.

ACRV | NDAQ

Overview

Corporate Details

ISIN(s):: US0048901096
LEI:
Country:: United States of America
Address:: 480 ARSENAL WAY, SUITE 100, 2472 WATERTOWN
Website:: https://acrivon.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology. The company leverages its proprietary Acrivon Predictive Precision Proteomics (AP3) platform to develop targeted cancer therapies. The AP3 platform utilizes phosphoproteomics to analyze the biologic drivers of a patient's cancer, enabling the creation of predictive 'OncoSignature' tests. This method is designed to match drug candidates with patients whose tumors are most likely to respond, aiming to improve therapeutic outcomes beyond what is achievable with genomics. Acrivon's pipeline is led by ACR-368, a selective kinase inhibitor in Phase 2 clinical trials for various solid tumors. The company also advances its internally developed programs and seeks strategic partnerships to apply its AP3 platform to co-develop predictive tests for external drug candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Acrivon Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Acrivon Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Acrivon Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Model Solution Co., Ltd. One-stop prototyping & low-volume production for IT, electronics, and medical hardware.	South Korea	417970
Modus Therapeutics Holding AB Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.	Sweden	MODTX
Moleculin Biotech, Inc. Developing therapies for hard-to-treat tumors (like AML) and viruses.	United States of America	MBRX
Molecure S.A. Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.	Poland	MOC
Moolec Science SA Uses Molecular Farming to grow animal proteins in plants for food, feed, and supplement industries.	United States of America	MLEC
MoonLake Immunotherapeutics Developing Nanobody therapies for inflammatory and immunologic diseases like psoriatic arthritis.	United States of America	MLTX
Mural Oncology plc Developing cytokine-based immunotherapies for difficult-to-treat cancers and solid tumors.	United States of America	MURA
Mural Oncology PLC Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.	Ireland	MURA
N2OFF, Inc. Sustainable agri-tech for food preservation, emissions reduction, and renewable energy.	United States of America	NITO
NANO MRNA Co.,Ltd. Biotech IP generator developing and licensing mRNA therapeutics using proprietary delivery systems.	Japan	4571